Australia markets closed

Alterity Therapeutics Ltd (PBN.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.0050+0.0010 (+25.00%)
At close: 08:05AM CEST
Full screen
Previous close0.0040
Open0.0050
Bid0.0030 x 0
Ask0.0050 x 0
Day's range0.0050 - 0.0050
52-week range0.0015 - 0.0125
Volume2,500
Avg. volume41,983
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

    MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA. Title:Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Frie

  • GlobeNewswire

    Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

    MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme. The cash refund relates to the cost of e

  • GlobeNewswire

    Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

    – Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that thr